Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care

Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Grothey, Axel, George, Suzanne, van Cutsem, Eric, Blay, Jean-Yves, Sobrero, Alberto, Demetri, George D.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2014
Témata:
Symptom Management and Supportive Care
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4041675/
https://ncbi.nlm.nih.gov/pubmed/24821824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0059
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky